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Abstract
Small-cell lung cancer (SCLC) is the most aggressive lung cancer subtype and lacks effective early detection
methods and therapies. A number of rare paraneoplastic neurologic autoimmune diseases are strongly associated
with SCLC. Most patients with such paraneoplastic syndromes harbor high titers of antibodies against neuronal
proteins that are abnormally expressed in SCLC tumors. These autoantibodies may cross-react with the nervous
system, possibly contributing to autoimmune disease development. Importantly, similar antibodies are present in
many SCLC patients without autoimmune disease, albeit at lower titers. The timing of autoantibody development
relative to cancer and the nature of the immune trigger remain to be elucidated. Here we review what is currently
known about SCLC-associated autoantibodies, and describe a recently developed mouse model system of SCLC
that appears to lend itself well to the study of the SCLC-associated immune response. We also discuss potential
clinical applications for these autoantibodies, such as SCLC diagnosis, early detection, and therapy.
Introduction
Lung cancer is the leading cause of cancer-related death
in the world, claiming the lives of 1.3 million individuals
worldwide in 2007 [1]. In the United States, lung cancer
killed over 150,000 Americans in 2009 [2,3] and caused
more deaths than breast, prostate, pancreatic, and colon
cancer combined. Small-cell lung cancer (SCLC), a
highly malignant tumor thought to originate from pri-
mitive neuroendocrine cells in the lung [4], accounts for
up to 15% of all newly diagnosed lung cancers [5].
Cigarette smoking is the major cause of SCLC, where
both the smoking intensity (cigarettes/day) and the
number of years of smoking increase the risk of SCLC
development [6]. Recently, it was shown that repetitive
nicotine exposure induces many malignant features in
SCLC cells, including increased adhesion, enhanced
migration, and resistance to chemotherapy [7]. Initially,
SCLC patients respond well to chemotherapy. However,
relapses are inevitable as patients become resistant to
cytotoxic treatment [8]. Despite treatment, the relative
5-year survival is only 6.4% [3], making SCLC the most
aggressive lung cancer subtype.
There are as yet no effective early detection tools for
SCLC. It is most often diagnosed due to symptoms asso-
ciated with disseminated disease, such as bulky
intrathoracic malignancy or distant metastases. Cough,
shortness of breath, and chest pain are the most com-
mon local symptoms, and distant signs of the disease
include weight loss and weakness. After presentation of
symptoms, histological analysis of bronchoscopic biopsy
samples and cytological study of fine-needle aspiration
(FNA), transbronchoscopic needle aspiration (TBNA),
or endoscopic ultrasound (EUS)-guided fine-needle
aspiration (EUS-FNA) samples are common approaches
to confirm SCLC diagnosis [9-12]. The cancer is defined
as a malignant epithelial tumor consisting of small cells
with altered cytoplasm, ill-defined cell borders, granular
nuclear chromatin, and absent or inconspicuous
nucleoli. The cells can be round, oval, or spindle-shaped
[13]. It can be difficult to pathologically distinguish
SCLC from other lung malignancies, including neuro-
blastoma, embryonal rhabdomyosarcoma, desmoplastic
small round cell tumor, primitive peripheral neuroecto-
dermal tumors [14], poorly differentiated squamous cell
carcinomas, and large cell carcinomas [10]. Epithelial
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markers can be employed to differentiate SCLC tumors
from the aforementioned lung malignancies. Sampling
error is the most commonly reported cause of false
negatives in lung FNA cytology [10,15]. SCLCs are
centrally located, and accessing them by FNA is more
difficult in comparison to peripherally located adenocar-
cinomas and metastatic neoplasms [10]. In addition, the
small size of the cells increases the chances of crushing
the sample by biopsy forceps or distorting the sample
during needle aspiration [16]. Given that accurately
diagnosing SCLC can be difficult, the development of
additional methods, such as detection of molecular mar-
kers associated with this disease, may increase the effi-
cacy of diagnosis. Molecules that might be suitable for
this purpose are SCLC-associated autoantibodies. Exam-
ples of such antibodies are those found in paraneoplastic
neurologic syndromes associated with SCLC.
Paraneoplastic neurologic syndromes (PNS) are
defined as cancer-associated neurological diseases that
d a m a g en e u r o n a lt i s s u e si nas i t er e m o t ef r o mt h e
tumor (unrelated to metastasis) [17]. PNS patients typi-
cally harbor antibodies directed against neuronal anti-
gens that are abnormally expressed in the tumor. Thus,
the tumor and the immune system are both implicated
in the development of PNS [18-20]. A number of PNS
are strongly associated with SCLC. They are severely
debilitating and often are the cause of death in SCLC
patients who are affected by them. While these autoim-
mune diseases are quite rare, affecting a small percen-
tage of SCLC patients [18], the characteristic antibodies
can actually be found in a substantial fraction of SCLC
patients without neurological symptoms, albeit at low
titers. This suggests that these antibodies may have uti-
lity for early detection and diagnosis of SCLC. In order
to be of use for early detection, the timing of the anti-
body response in relation to that of SCLC development
and progression has to be clearly established. In the case
of SCLC-associated PNS, the diagnosis of the neurologi-
cal disease often antedates that of the tumor [18,21],
suggesting that the body’s immune system can detect
the presence of SCLC before the cancer becomes symp-
tomatic. If such antibodies were to generally arise prior
to tumor metastasis in SCLC patients, they could poten-
tially provide an avenue for early detection.
The mechanism by which autoimmunity develops in
SCLC remains to be elucidated. For example, it is
unclear whether the antigens that prompt an immune
response are in any way different from those in normal
tissue. If these antigens exhibited cancer-specific
changes responsible for triggering an antibody response,
they might not only be useful for the development of
tools for (early) detection, but also for imaging and
treatment. Thus, elucidating the basis of immune reac-
tivity in SCLC is of great importance. The study of
SCLC-associated PNS offers a potential window into the
relationship between SCLC and the immune response.
SCLC-related autoantigens and autoantibodies
Overview of paraneoplastic syndromes associated with
SCLC
Many SCLC-associated autoantigens are normally
expressed in the nervous system, but they become
abnormally expressed in the tumor, classifying them as
onconeural antigens. The biological characteristics of
these autoantigens can be broadly divided into four
categories: 1) neuromuscular junction proteins; 2) vesi-
cle-associated nerve-terminal proteins; 3) neuron-speci-
fic DNA or RNA-binding proteins; and 4) neuronal
signaling proteins [22]. Several different onconeural
antigens can give rise to the same disease phenotype, as
seen in Table 1. Presumably this is because these differ-
ent antigens are normally expressed in the same cells,
and the autoimmune response attacks the same parts of
the nervous system. The mechanism by which the
immune system identifies these antigens as foreign
remains poorly understood. Importantly, the immune
response includes the generation of autoantibodies,
which have been crucial tools in gaining an understand-
ing of the cause and pathology of these cancer-
associated syndromes.
The nomenclature of SCLC-associated antibodies and
antigens has evolved over time, largely because the
specific antigens were originally unknown, and the anti-
bodies were classified based on reactivity with whole
cells or whole cell lysates. For example, ANNA (anti-
neuronal nuclear antigen) reactivity was later reclassified
as anti-Hu to reflect the fact that these antibodies target
the Hu proteins [23-26]. Currently, there are at least 20
known antigens in SCLC-associated PNS. Interestingly,
patients are often positive for more than one SCLC-
associated autoantibody [27-32], and may have several
paraneoplastic syndromes [33,34]. The possible mechan-
isms causing immunoreactivity as well as the possible
pathogenesis of SCLC-related autoimmunity will be dis-
cussed later in this review.
The SCLC-associated autoantigens/autoantibodies
identified to date are summarized in Table 1. Three dif-
ferent types of SCLC-associated PNS and their target
autoantigens are discussed in more detail below as
examples: 1) paraneoplastic encephalomyelitis/sensory
neuronopathy (PEM/SN), in which Hu proteins are a
target, 2) Lambert-Eaton myasthenic syndrome (LEMS),
in which voltage-gated calcium channels (VGCC) and
SOX proteins are targets, and 3) cancer-associated reti-
nopathy (CAR), in which recoverin is a target.
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Page 2 of 19Table 1 Comprehensive list of SCLC-associated autoantigens and autoantibodies
Autoantigen Antibody Paraneoplastic
Symptoms
% of antibody-
positive PNS
patients who have
SCLC
% SCLC patients
without PNS who
have antibodies
Reference
“Well characterized” onconeural autoantibodies [56]
Amphiphysin Anti-amphiphysin PEM/SN, SMS 2.9 1.4 [27,29]
Collapsin response-
mediator protein (CRMP5/
POP66)
Anti-CRMP/Anti-CV2 PEM/SN 77 9 [29,142,183-185]
HuB(Hel-N1)/ELAVL2, HuC/
ELAVL3, HuD/ELAVL4
Anti-Hu PEM/SN 85 16-25 [36,42,88,173,186]
Neuro-oncological ventral
antigen (Nova)
Anti-Ri (ANNA2)/
anti-Nova
PNS; POMA 0 4.5 [29,105,187,188]
Paraneoplastic Ma proteins
(PNMA1)
Anti-Ma PEM/SN ND ND [189,190]
PNMA2 Anti-Ta PEM/SN ND ND [190]
Surface-binding autoantibodies
P/Q type voltage-gated
calcium channel (VGCC),
MysB
Anti-VGCC LEMS; PCD 40-98 2-5 [50,66,73,74,76,163,164,191,192]
Voltage-gated potassium
channel (VGKC)
Anti-VGKC LEMS ND ND [166,193]
a-amino-3- hydroxy-5-
methyl-4-isoxazole-propionic
acid receptor (AMPAR)
Anti-AMPAR; Anti-
GluR1/2
LEMS ND ND [194]
Protein tyrosine
phosphatase receptor type
N (PTPRN)
Anti-IA-2 LEMS 25 10 [195]
GABAB receptor Anti-GABAB LEMS 33 ND [196]
Nicotinic acetylcholine
receptors (AChRs)
Anti-AChR (a3) Autonomic
neuropathy
3-5 ND [197]
Other autoantibodies described in literature and/or case reports
280-kDa cerebellar protein Anti-Purkinje cell
cytoplasmic
antibody (PCA)-2
LEMS 53 2 [29,198]
170-kDa brain protein Anti-neuronal
nuclear
autoantibody type 3
(ANNA-3)
LEMS 45 ND [199]
BR serine/threonine kinase
(BRSK)2
Anti-BRSK2 PNS ND 4 [200]
a-Enolase Anti-enolase CAR ND 0 [201,202]
Glutamic acid decarboxylase
(GAD) 2
Anti-GAD65
(GAD65A)
LEMS 63 9-19 [195,203]
Recoverin Antiretinal, Anti-Rc CAR 45 10-15 [83,84,87,201,204]
Sry-like high mobility group
box (SOX)1,2
Anti-SOX LEMS 64 22-36 [30,31,78,80,205]
Synaptotagmin (SYT)1 Anti-SYT LEMS 5 ND [206]
Synaptophysin Anti-synaptophysin PNS ND 5 [104]
ZIC2 ZIC4 (derived from zinc
fingers of cerebellum)
Anti-ZIC PND 29 16 [80,207,208]
Paraneoplastic encephalomyelitis sensory neuronopathy (PEM/SN); Lambert-Eaton myasthenic syndrome (LEMS); Cancer-associated retinopathy (CAR);
paraneoplastic opsoclonus-myoclonus ataxia (POMA); paraneoplastic cerebellar degeneration (PCD); paraneoplastic neurological syndromes (PNS); Paraneoplastic
neurologic disorder (PND); Paraneoplastic stiff man syndrome (SMS); Not determined (ND).
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(PEM/SN) and the Hu antigens
Anti-Hu autoantibodies were first detected in SCLC
patients with subacute sensory neuropathy [23-25,35].
Serum from a SCLC patient with PEM/SN was used to
screen a lambda cerebellar expression library, which led
to the identification of an antigen that was named
HuD [36]. HuD belongs to a family of four related RNA-
binding proteins. These proteins are homologous to the
Drosophila melanogaster protein Elav (embryonic lethal,
abnormal visual) which plays a role in eye and central
nervous system development of the fly [36]. Expression
of three of the Hu proteins–HuB/Hel-N1/ELAVL2,
HuC/ELAVL3, and HuD/ELAVL4–is restricted to the
nervous system and gonads, while expression of the
fourth, HuR/ELAVL1, is ubiquitous [37]. In vertebrates,
neuronal Hu proteins play a role in neuron-specific RNA
processing and neural development [36,38-40].
About 85% of PEM/SN patients have underlying SCLC,
and these patients harbor high titers of autoantibodies
[26,41,42] that react strongly against all three neuronal
Hu proteins and weakly against HuR [24,26,43,44] (Table
1). Hu proteins contain three RNA recognition motifs
(RRMs). A short presumably unstructured N-terminal
region precedes RRM1, followed by RRMs 2 and 3, which
are separated by a hinge region. Using Hu deletion con-
structs, the pattern of anti-Hu reactivity has been exam-
ined in anti-Hu positive PEM/SN patients with SCLC
[45,46], in mice immunized with full-length HuD [46], in
SCLC patients with and without PEM/SN [47], and in a
SCLC mouse model system [48]. Consistent reactivity
against the RRM1-containing N-terminal region of
the protein was common among all of the studies, sug-
gesting RRM1 may be the key target of the autoimmune
response.
All SCLC tumors express neuronal Hu antigens; how-
ever, PEM/SN presents itself in less than 1% of all SCLC
patients [36,41]. It is unknown why a small fraction of
patients develop the autoimmune disease while the vast
majority does not. Interestingly, 16-25% of SCLC
patients without paraneoplastic neurological autoim-
mune syndromes have detectable titers of anti-Hu anti-
bodies in their serum, albeit at much lower levels than
PEM/SN patients (Table 1, Figure 1A) [26,49-52]. While
the frequency of anti-Hu antibodies in SCLC is too low
to be of value for SCLC diagnosis or early detection,
one could envision that a panel of SCLC-associated anti-
gens will increase sensitivity.
Lambert-Eaton myasthenic syndrome and the voltage-
gated calcium channel and SOX1 antigens
Lambert-Eaton myasthenic syndrome (LEMS) is an
autoimmune disorder of the neuromuscular junction
and is characterized by muscle weakness, absence of
reflexes, and autonomic dysfunction [53]. An underlying
SCLC tumor is found in up to 50% of LEMS patients
[54], and discovery of SCLC can occur more than five
years after diagnosis of the autoimmune disease [55]. It
has been difficult to determine whether the tumor pre-
cedes the neurologic disorder or vice versa, but the diag-
nosis of LEMS initiates a tumor search based on the
high degree of correlation between LEMS and SCLC
[56,57], and the detection of various autoantibodies has
aided in cancer diagnosis. Multiple antigens are asso-
ciated with LEMS, and some LEMS patients with SCLC
will exhibit one or multiple autoantibodies (Table 1),
including anti-voltage-gated calcium channel (VGCC)
and anti-SOX1.
SCLC tumors ectopically express functional neuronal
presynaptic P/Q-type voltage-gated calcium channels
(VGCCs) [58] (Figure 1B). These are among five types
of high voltage-activated neuronal calcium channels: L,
Figure 1 Association between SCLC, paraneoplastic syndromes,
and (A) anti-Hu, (B) anti-voltage-gated calcium channels
(VGCC), (C) anti-SOX1, and (D) anti-recoverin (Rc)
autoantibodies. Arrows provide further description of distinct
groups within subsections of each circle or oval (see Table 1 for
references).
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make up this multimeric transmembrane protein, and it
has been reported that the a-1 subunit may contain the
antigenic epitope to which anti-VGCC antibodies bind
[62-64]. A key aspect of the antibodies against the P/Q-
type VGCC is that they are able to bind to extracellular
targets [65] and have been shown to disturb calcium-
dependent transmission across the neuromuscular junc-
tion [66], indicating that they may play a direct role in
the pathogenesis of LEMS. Additional evidence support-
ing this hypothesis include: 1) LEMS IgG reduced the
number of VGCCs on cultured SCLC cell lines [67-69],
2) treatment of SCLC tumor (radiation therapy, che-
motherapy, or resection) was followed by clinical remis-
sion of LEMS [65], and 3) mice injected with LEMS IgG
displayed physiological and morphological abnormalities
similar to the human disease [70-72]. Similar to the Hu
p r o t e i n s ,i ti sb e l i e v e dt h a tt he misexpression of neuro-
nal VGCCs in SCLC initiates an immune response. In
the case of LEMS, the antibodies are thought to cross-
react with VGCCs in cholinergic nerve terminals at the
neuromuscular junction and in the cerebellum
[66,73,74]. Importantly, patients with the idiopathic
form of LEMS (NT-LEMS) also harbor high titers of
anti-VGCC autoantibodies [75-77], making it difficult to
distinguish between paraneoplastic and nonparaneoplas-
tic LEMS. This calls into question the potential utility of
this particular type of antibody for diagnosis or early
detection of SCLC, since it would lower the specificity
of any resulting test.
Recently, anti-glial nuclear antigen (anti-AGNA) anti-
bodies have been described as among the many autoanti-
bodies associated with LEMS [78]. Though their role in
the pathogenesis of the paraneoplastic disease remains
unknown, the antibodies present themselves in a large
percentage of SCLC patients, more so than most well
characterized autoantigens (see Table 1). The antibodies
bind to the nuclei of Bergmann cells, a specialized glial
cell type exclusively found in the cerebellar cortex [79].
Screening a fetal brain library with AGNA-positive sera
from SCLC patients led to the identification of SOX1
(Sry-like high mobility group box) as an antigen of anti-
AGNA positive patients with SCLC-associated LEMS
(Table 1) [30,80]. The SOX family of DNA-binding tran-
scription factors is important in the development of the
nervous system [81] and contains a highly conserved
HMG-box DNA-binding domain. Of all LEMS patients
with confirmed SCLC, approximately 64% have detect-
able titers of anti-SOX1 antibodies (Figure 1C). Idio-
pathic LEMS cases (without SCLC) rarely show positive
reactivity to SOX1 and no anti-SOX antibodies have
been detected in healthy controls, indicating that the
SOX1 autoantibodies may be highly specific for SCLC
[30,31]. In the SCLC patient population without LEMS,
up to 36% harbor antibodies to one or more SOX protein
family members (Table 1). Thus, inclusion of SOX anti-
gens in a SCLC antigen panel could increase sensitivity
and specificity of a future antibody test aimed at SCLC
diagnosis or early detection.
Cancer-associated retinopathy and the recoverin antigen
Cancer-associated retinopathy (CAR) is characterized by
the degeneration of photoreceptors in the presence of
cancer, leading to blindness. A 26 kDa retinal protein
was identified as a key component in the immunologic
events that accompany CAR [82]. Serum antibodies
from CAR patients with concurrent SCLC were used to
isolate the corresponding gene by screening against a
cDNA library made from human retina [83]. Sequence
analysis revealed high homology with the bovine photo-
receptor protein recoverin [84]. Recoverin, a calcium-
binding protein in the retina, is involved in guanylate
cyclase activation and function; guanylate cyclase is an
essential component of the phototransduction cascade
initiated by rhodospsin [85]. It has been shown that
antibodies directed against recoverin can neutralize its
activation of guanylate cyclase [85], which could, in
turn, interfere with photoreceptor function and lead to
the loss of photoreceptors, which is characteristic of
CAR [86]. Thus, these SCLC-associated autoantibodies
might play a role in the autoimmune pathology.
Just as with anti-Hu reactivity, anti-recoverin (anti-Rc)
antibodies can also be found in SCLC patients without
paraneoplastic disease (Figure 1D). In an analysis of
tumor tissues and sera from 143 patients with lung can-
cer, 68% of SCLC tumors expressed recoverin while 15%
of sera from these patients were positive for anti-Rc
antibodies. None of the 143 patients had CAR [87]. The
presence of anti-Rc antibodies in a substantial fraction
of SCLC patients suggests that recoverin might show
promise for SCLC detection as part of an antigen panel.
Induction of immuno-responsiveness in SCLC
The mechanisms that trigger and maintain an autoim-
mune response in cancer patients are poorly under-
stood. An autoimmune response is a specific immune
response to a self-antigen, and autoimmune diseases
occur because the immune system is incapable of discri-
minating between self-antigens that are normally
expressed and those that are abnormally or ectopically
expressed. Some SCLC-associated autoantigens, such as
the Hu and SOX1 proteins, are intracellular antigens.
The following sections will discuss various hypotheses
concerning the induction mechanism of immuno-
responsiveness against self-antigens, including abnormal
expression of proteins, tolerance disruption, cross-reac-
tion with membrane antigens, and protein modifications
that generate “neo-antigens”.
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privilege of neurons
SCLC-associated autoimmunity may arise as a conse-
quence of abnormal self-antigen expression by tumor
cells. Ectopic expression of a self-antigen alone is not
sufficient to initiate an immune response; the immune
system must somehow be activated. It is understandable
that a mutation or modification of a self-antigen could
render it foreign; however, if this is not the case, another
explanation must exist. Many tumor-associated antigens
are not unique to tumor cells. Most SCLC-associated
antigens are normally expressed in the nervous system
and gonads, and the tumor antigen and natural antigen
appear to be identical. In these cases, the antigen may
present in a way that the immune response is unaccus-
tomed to, either at an increased level of expression or
altered localization, which could be detected by the
immune system, initiating an immune response.
An important question to address is why only a frac-
tion of patients harbor an immune response when many
o ft h ea n t i g e n i cp r o t e i n sa r ea b e r r a n t l ye x p r e s s e di n
almost all SCLC tumors? For example, 16-25% of SCLC
patients have an anti-Hu response without neurological
disease [26,31,49,52,88] even though all SCLC tumors
express the antigen [89]. This suggests that those cells
expressing the antigen may be immune privileged,
allowing evasion of an immune response. A recent study
found that HuD-specific CD8+ T cells were normally
present in C57BL/6 mice, but these T cells did not
expand upon immunization with an adenovirus expres-
sing HuD. The T cells were stimulated only when the
splenocytes from these immunized mice were stimulated
in vitro. These cells were able to recognize the antigen
in vivo, but were prevented from becoming effector
cytotoxic T cells, suggesting that the mice were strongly
tolerant to the self-antigen HuD protein. Furthermore,
after HuD immunizations or HuD CD8+ T cells through
adoptive transfer, these mice did not develop evidence
of neurologic dysfunction or abnormality. Further evi-
dence for tolerance to HuD comes from experiments
with HuD null mice, where HuD is not a self-antigen.
These mice generated functional HuD-specific T cells,
and these cells were directly activated without the need
for in vitro stimulation with a peptide [90]. Taken
together, these results demonstrated a robust tolerance
to HuD in vivo.
Most SCLC-associated autoantigens are normally
expressed in a neuron-specific manner. Neurons do not
normally express major-histocompatibility complex
(MHC) class I molecules [91], thus they may be immune
privileged cells that can evade immune surveillance. It
was observed that some SCLC tumors from patients
with PEM/SN did express MHC class I molecules,
whereas amongst 20 tumors from patients with
detectable anti-Hu autoantibodies and no PEM/SN, only
one showed modest expression of MHC class I mole-
cules [41]; tumors from most seronegative patients did
not express MHC proteins. Together, these studies indi-
cate that tolerance to neuronal antigens may be present,
and that its disruption might contribute to SCLC-asso-
ciated autoimmunity.
Modifications of self-antigens to generate “neo-antigens”
An alternative hypothesis for the autoimmune response
in SCLC is that the antigenic protein might be mutated
or modified in a way that renders it foreign to the
immune system. It is possible that the tumors express
similar, but not identical forms of the antigen. For
example, mutations or alternative splicing may generate
different forms of the protein. In a recent study, the
HuD sequence of four SCLC tumors and five SCLC cell
lines was determined [92]. A missense mutation was
identified in two tumors, but it was unclear whether the
mutations were single nucleotide polymorphisms (SNPs)
or somatic mutations. None of the cell lines showed
HuD mutations, although several had SNPs. A previous
study of 18 SCLC cell lines, including one from the
tumor of a patient with PEM/SN, also failed to identify
mutations or rearrangements in HuD [93]; the same was
true in an analysis of paraneoplastic SCLC tissue [94].
However, these studies did not examine the related
genes HuB and HuC, which are often misexpressed in
SCLC and to which anti-Hu autoantibodies are cross-
reactive. No mutations were found in the cerebellar
degeneration-related (cdr2) gene, which encodes a neu-
ron-specific protein in breast and ovarian tumors asso-
ciated with PCD [95]. Overall, there is little evidence for
the involvement of mutations in SCLC-associated auto-
immunity, however further studies are needed to elimi-
nate this as a potential factor.
Another possible explanation for immunogenicity of
SCLC-associated autoantigens is that proteins triggering
the autoimmune response might carry abnormal post-
translational modifications. Over 140 unique amino acids
and amino acid derivatives are reported to exist in proteins
as a result of post-translational modification [96]. Such
modifications include glycosylation, phosphorylation,
methylation, acetylation, deamidation, and isomerization
(reviewed in [97,98]). These modifications can be enzyme-
mediated or spontaneous. Abnormal post-translational
modifications can lead to the generation of “neo-self” anti-
gens which the immune system recognizes as foreign and
to which it mounts an immune attack. For example,
experimental autoimmune encephalomyelitis (EAE) is only
induced in a murine model for human multiple sclerosis
when mice are immunized with an acetylated N-terminal
peptide of myelin basic protein (MBP-Ac1-11); no T cells
are stimulated and no EAE is elicited upon immunization
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ber of autoimmune diseases, including multiple sclerosis,
experimental allergic encephalomyelitis, systemic lupus
erythematosus, and rheumatoid arthritis, are associated
with post-translational modifications (reviewed in
[96,98,100]). Recently, changes in IgG Fc N-glycosylation
were observed in LEMS and myasthenia gravis (MG)
patients [101]. Antibodies elicited as a result of modified
self proteins are often able to bind both the modified and
unmodified form of the protein, possibly by epitope
spreading; however, the T cell response is usually specific
for the modified form, retaining tolerance for the normal
protein [97].
To our knowledge, the association between post-
translational modifications of SCLC-associated autoanti-
gens and SCLC-related autoimmunity has not been
examined. It is possible that post-translational modifica-
tion of neuronal proteins in SCLC tumors initiates an
immune response which may cross-react with native
proteins in the healthy nervous system and, in extreme
cases, leads to paraneoplasticd i s e a s e .T h e r e f o r e ,t h e
role of post-translational modification as a trigger of
SCLC-associated autoimmunity should be thoroughly
investigated.
Pathogenicity of SCLC-associated autoimmune
responses
Understanding the pathogenesis of SCLC-associated
PNS is important to elucidate the mechanism by which
t h ei m m u n er e s p o n s ea r i s e sa sw e l la st oc l a r i f yt h e
potential limitations of harnessing the immune system
to fight cancer. If mutated or aberrantly modified pro-
teins originating from the cancer trigger the SCLC-asso-
ciated immune responses then one might expect the
response to be tumor-specific. How would reactivity
spread to the native protein and lead to destruction of
healthy tissue? One mechanism that has been proposed
is epitope spreading [97,102]. Epitope spreading is the
gradual expansion of the spectrum of specificities recog-
nized in B and/or T cell-mediated immune responses.
Evidence for epitope spreading has been demonstrated
by immunization experiments with a single peptide
derived from an autoantigenic protein, giving rise to a T
cell response or autoantibody production directed
against epitopes that did not overlap with the immuniz-
ing peptide [102]. Analysis of B and T cell reactivity in
autoimmune diseases does, however, suggest that the T
cell response is frequently specific for the modified anti-
gen, while the B cell response is more cross-reactive
[97]. This may be related to the mechanism by which
antigens are displayed by MHC molecules and recog-
nized by the T cell receptors [97]. In SCLC-associated
autoimmunity, multiple epitopes are often recognized
within a single antigen [91,103], also supporting a role
of epitope spreading in the pathogenicity of SCLC-asso-
ciated paraneoplastic syndromes.
The tissue naturally expressing SCLC-associated auto-
antigens will affect the pathogenesis of PNS. In the case
of SCLC-related autoimmunity, most of the autoantigens
are neuronal; thus, certain parts of the nervous system
would be targeted and affected. In addition, the cellular
localization of the antigen in its natural context will also
play a role. Synaptic proteins, for example, are more
likely to be expressed on the cell surface [104], and a
pathogenic role of autoantibodies against these antigens
is therefore more likely than of antineuronal antibodies
directed against intracellular proteins. Cell surface anti-
gens can be directly recognized by antibodies and CD8+
T cells, which would result in a directed immune attack
and subsequent apoptotic cell death of the offending
cell. Apoptotic cells can present altered cleavage pro-
ducts and post-translationally modified self-proteins on
surface blebs, further promoting autoimmunity [97].
Antibody binding may also affect the function of the
target protein. In SCLC-associated LEMS, voltage-gated
calcium channels (VGCCs) are found both in the tumor
and the presynaptic cholinergic-synapse and cerebellar
Purkinje cells of the nervous system [66]. VGCCs are
transmembrane proteins, and antibodies reacting with
them in the tumor and the nervous system bind and
disrupt the normal structure of the extracellular protein,
possibly contributing to the development of LEMS.
Anti-Nova antibodies (Table 1) have been shown to play
an inhibitory role on Nova-1 binding to its RNA target
[105], suggesting that the antibodies may disturb the
function of the protein. Whether this biological effect
contributes to the formation of paraneoplastic opsoclo-
nus-myoclonus ataxia (POMA) is unknown.
It has been proposed that antibodies or cytotoxic CD8+
T cells can cross-react with antigens in the nervous sys-
tem by penetrating the blood-brain barrier–ap h y s i c a l
barrier separating the central nervous system from sys-
temic circulation and restricting the passage of solutes
into cerebrospinal fluid. These antibodies and T cells can
then bind to the antigen expressed on the neurons and
impair neuronal activity, triggering apoptosis [22]. For
example, it has been hypothesized that anti-recoverin
antibodies present in peripheral blood can penetrate the
blood-retina barrier and become internalized into photo-
receptor cells expressing recoverin, which could block
recoverin function and lead to photoreceptor cell death
[106-108]. Some onconeural antigens, such as Hu pro-
teins, however, are normally expressed in the peripheral
nervous system neurons where the blood-brain barrier
does not exist [109]. Thus, an alternate model is likely in
those cases.
W h i l et h e r ei sa m p l ee v i d e n c ef o rar o l eo fa n t i b o d i e s
in the pathogenesis of PNS, there are also examples of
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For example, when mice were immunized with a HuD
DNA or HuD protein vaccine, no neurological disease
was observed even though an antitumor response that
inhibited the growth of an implanted neuroblastoma
was observed. Furthermore, passive transfer of IgG from
anti-Hu patients to animals did not induce an autoim-
mune response [110,111]. This suggests that a correla-
tion exists between antitumor immunity and the
presence of the antibodies, but that the antibodies are
not causing the autoimmune disease. Thus, the patho-
genicity of SCLC-related autoantibodies may be depen-
dent on the antigen and its effect on its target cell.
Cellular immunity has been shown to play a role during
the course of SCLC-associated PNS. Several groups have
reported a T cell response in anti-Hu positive patients,
and a HuD-specific cytotoxic T cell response has been
implicated in the development of PEM/SN [112-115].
A subpopulation of nontoxic T cells was also identified
in PEM/SN patients, indicating that both classical cyto-
toxic T cells and noncytotoxic T cells may play roles in
pathogenesis [114]. In seeming contrast to these obser-
vations, one group showed no evidence of HuD-specific
T cells in the cerebrospinal fluid of SCLC-associated
PEM/SN patients [116,117]. However, the authors noted
that the assay used may not have been sufficiently sensi-
tive. Thus, the role of antigen-specific T cells in the
pathogenesis of SCLC-associated autoimmunity is still
under debate. It has been shown that major-histocom-
patibility complex (MHC) class I and MHC class II anti-
gen-presenting molecules in neurons can be recognized
by T cells which can kill neurons [118]. Intracellular
proteins can be presented to T cells on the surface of
MHC class I molecules. However, neurons do not nor-
mally express MHC class I molecules [91], indicating
that these cells may be immune privileged, allowing eva-
sion of T cell recognition.
Recently, attention has turned to the role of CD4+
CD25+ regulatory T cells (Treg), which are suppressor
cells that maintain immune tolerance. Treg populations
generally increase in and around cancer tissues, which
potentially causes the down regulation of both effector
T cell function and antitumor immunity, thereby contri-
buting to cancer growth [119,120]. However, LEMS and
PEM/SN patients exhibited a down regulation of these
T cells in comparison to SCLC patients without LEMS
or PEM/SN [121], suggesting Treg dysfunction may play
a role in the PNS development.
In summary, many questions remain about the patho-
genicity of the SCLC-associated immune response, and
the possibility that distinct mechanisms play a role in
different paraneoplastic syndromes further increases the
complexity of this disease state. Various hypotheses
about the ectopic expression of autoantigens, the
molecular state of antigens themselves, and the role of
the immune system and the pathogenicity of antibodies
and T cells are currently under study. Animal models
are a promising tool for testing these various hypotheses
and helping to elucidate the pathogenesis of autoimmu-
nity as well as the autoimmune trigger.
Animal models as tools for understanding the
etiology of SCLC-associated autoimmunity
As outlined above, the underlying causes of SCLC-related
autoimmunity and how it leads to pathology remain
poorly understood despite many years of investigation.
The rapid progression of SCLC coupled with the rarity of
the related autoimmune diseases make studies in human
patients challenging. Animal models can be extremely
helpful for the investigation of disease development and
progression; they allow many analyses that are difficult or
impossible to carry out in human patients.
Generating animal models that accurately represent
human SCLC-associated paraneoplastic neurological
syndromes has been very challenging. For example, the
passive transfer or intraventricular injection of anti-Yo
antibodies from patients with PCD (Table 1) into mice
and rats did not induce disease in the animals [122,123].
When HuD was used as either a protein or DNA to
immunize mice, a strong anti-Hu response and high
titers of T cell inflammatory infiltrates were observed in
all immunized animals [110,111]. Although some insight
into the anti-Hu immune response was gained from
these studies, these animals did not develop neurological
symptoms or neuropathological abnormalities. The
transfer of autoreactive T cells against the PNMA1 anti-
gen in rats resulted in no clinical signs of neurologic
disease despite an inflammatory response in the brains
of the animals [124]. More recently, two mouse models
with immunologically induced retinopathy associated
with elevated recoverin antibodies were developed. In
one case, mice were immunized with recombinant reco-
verin three times. In the other, mice were injected with
hybridoma cells that produce a monoclonal antibody
targeting recoverin. In both models, retinopathy was
observed, suggesting that this kind of approach can be
used to mimic this particular type of autoimmunity
[125]. In another recent study, stiff person syndrome-
like symptoms were induced in rats through repetitive
intrathecal application of anti-amphiphysin IgG antibo-
dies, including stiffness of trunk and limb muscles, mus-
cle spasms, and gait abnormalities [126]. One weakness
of all the aforementioned models is that immunogenicity
was induced by exogenous introduction of antigens or
antibodies and not by the “natural” presence of SCLC.
The development of a SCLC animal model and the
study of its associated immune response would provide
a better model system for SCLC-associated PNS.
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Expression of proneural transcription factor human
achaete-scute homolog-1 (hASH-1), which is highly
expressed in SCLC, under the control of the bronchial
epithelial-expressed Clara cell CC10 promoter in mice
was not successful. Even though these mice exhibited
rapid hyperplasia after being crossed with a transgene
CC10-SV40 large T antigen, they developed adenocarci-
nomas that did not resemble human SCLC [127]. Other
attempts have been made using xenograft models with
SCLC cell lines or primary SCLC tumors [128-130].
However, these strategies require immune-compromised
animals, thereby limiting their utility for studies of auto-
immunity. Success was finally achieved through the con-
ditional knockout of the Rb and Trp53 genes in the
lungs of mice [131,132]. The inactivation of both genes
is commonly found during lung cancer pathogenesis
and has been identified in up to 90% of human SCLCs
[4,133]. Using a Cre-loxP system, “floxed” Rb1 and
Trp53 can be homozygously deleted in the lung epithe-
lium of transgenic mice through intratracheal instillation
of Adeno-Cre virus. All treated mice develop multiple
tumors with histopathology and immunophenotype
similar to human SCLC beginning around 200 days post
infection [131,132]. The prolonged lag time allows for
the monitoring of potential immune responses against
various SCLC-related autoantigens prior to the clinical
detection of the disease. Recently, it was observed that
the loss of p130, a cell cycle inhibitor related to Rb
[134] that normally suppresses SCLC development
[135], accelerates the development of SCLC in Rb/
Trp53-mutant mice. Rb/Trp53/p130 mutant mice may
thus provide an alternative mouse model of SCLC with
a shortened lag time [136].
Our laboratory examined the anti-Hu response in the
inducible Rb/Trp53 knock out mouse model system
[48]. Just like their human counterparts, tumors derived
from the SCLC mouse model expressed Hu proteins.
Interestingly, elevated anti-Hu antibodies were detected
in 14% of SCLC-prone mice, similar to the frequency of
above background anti-Hu response in human SCLC
patients. Furthermore, the pattern of reactivity against
the Hu protein family and Hu deletion constructs was
similar to that observed in human patients [45-47], sup-
porting the notion that the N-terminal part of the pro-
tein containing RRM1 may contain the epitopes that
bind to MHC and may be the key target of the autoim-
mune response. Thus, this mouse model system closely
mimics previously observed aspects of the anti-Hu
response in human SCLC patients.
The inclusion of a recombination-induced luciferase
gene in the SCLC model system enables cancer develop-
ment to be monitored by bioluminescence as well as by
small animal computed tomography (CT). This allows
for the timing of the anti-Hu response relative to the
clinical detection of the tumor to be measured. Initial
studies with a limited number of animals indicated that
anti-Hu antibodies could arise up to 100 days before the
cancer was clinically detectable (Figure 2). In this initial
published study, no neurological tests were performed
to determine whether the mice showed signs of para-
neoplastic disorder. While an antibody response is
detected in 16-25% of human SCLC patients, manifesta-
tion of PEM/SN is rare. If the mouse model parallels
the human situation, PEM/SN will be much less fre-
quent than an above background anti-Hu antibody
response. If PEM/SN ever develops in the context of
this model, this will likely require the analysis of a large
number of mice. However, even if PNS were rare in the
SCLC mouse, the development of an anti-Hu antibody
response in a substantial fra c t i o no ft h em i c es u g g e s t s
the SCLC mouse model should lend itself well to the
study of immune responses against other SCLC-asso-
ciated paraneoplastic antigens and to the elucidation of
the mechanism of SCLC-associated autoimmunity.
The SCLC mouse model may also shed light on
whether the induced autoantibodies antagonize cancer
progression. This is still a topic of debate in human
patients [28,31,41,42,50,52,88,137-144]. In humans,
some studies have noted a correlation between the pre-
sence of the autoantibodies and indolent tumor growth
[42,88,138]. Interestingly, in our initial small study with
SCLC-prone mice, we did observe one mouse that was
highly positive for anti-Hu autoantibodies yet lacked an
overt tumor [48]. While we did not detect a survival
benefit of an anti-Hu response in the initial mouse
study, we estimate that about 180 mice would be needed
to clearly show the presence or absence of an effect of
the anti-Hu response on survival [48].
In conclusion, the SCLC mouse model offers a highly
promising new window onto the development and con-
sequences of SCLC-related autoimmunity. To date, only
anti-Hu reactivity has been examined in this model sys-
tem, and it will be of great interest to test these mice
for other types of antibodies, such as those listed in
Table 1. Most importantly, the SCLC-prone mouse
model will lend itself to mechanistic studies of the
immune response and its timing relative to cancer
onset. It will also be a great tool to examine potential
clinical applications of autoantibodies and molecules tar-
geting the autoantigens, such as imaging and therapeutic
agents.
Potential clinical applications of SCLC-related
autoantibodies and their antigens
Early detection and screening strategies for SCLC
Effective early detection of any cancer (i.e. detection that
allows complete removal of lesions before they can
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related mortality. Ideally, this would be achieved by
non-invasive molecular imaging combined with biomar-
ker-based tools [145]. An effective screening method
must have high specificity and sensitivity, reduce overall
mortality, be acceptable to patients, and be cost effective
in order to be widely adopted [146].
To date, imaging has shown limited promise for the
early detection of SCLC. [
18F] fluorodeoxyglucose posi-
tron emission tomography (FDG-PET) scanning, a
method that has been used to detect SCLC tumors in
paraneoplastic patients positive for anti-Hu antibodies,
has not been shown to decrease mortality [147]. This
suggests that FDG-PET is unable to detect SCLC lesions
in time for curative resection. Low Dose Spiral Com-
puted Tomography (LDSCT) is under evaluation as an
early lung cancer detection modality. Studies from the
Early Lung Cancer Action Project (ELCAP) suggest that
annual spiral CT screening can detect lung cancer at a
curable stage and increase lung cancer survival
[148-151]. However, any early detection method causes
lead time bias; the favorable survival noted in the
ELCAP study is therefore not a valid measure of the
efficacy of screening [152]. In addition, LDSCT was
shown to incorrectly classify many non-calcified nodules
as cancers [153,154], potentially subjecting patients to
unnecessary follow-up procedures (scans, biopsies, or
resections), which are costly, invasive, and can result in
patient morbidity and mortality [149,155,156]. Recently,
it has been hinted that the National Lung Cancer
Screening Trial, a randomized control trial of high risk
long term smokers subjected to either LDSCT or X-ray
based screening [157], might show a reduction in mor-
tality in the LDSCT-screened group. The published
results of the study are therefore anxiously awaited so
that the potential benefits and drawbacks of screening
by LDSCT can be weighed and the guidelines for the
use of this tool can be established.
Whether this type of screening could benefit SCLC
patients is unclear. Early detection of SCLC through
imaging is especially challenging because SCLC can
metastasize when the primary lesion is still very small.
Small tumors are more challenging to detect because
they generate less signal. In addition, if SCLCs are small
Figure 2 Anti-Hu reactivity relative to SCLC detection and image-based screening of SCLC-prone mice. (A) Anti-Hu reactivity was
detected 40-100 days prior to clinical detection of SCLC. Graphs from the six highly positive mice are shown. The dotted line represents the
date of first clinical detection of tumor by CT scan and/or luminescence detection. The titer was determined by the highest fold dilution of
plasma or serum in which there was a positive Western blot signal against recombinant HuD protein. The time (in days) between the
measurement of a titer above background (titer > 5000) and clinical detection is indicated by a horizontal bar. SCLC tumor was not detected in
mouse 489556, though the mouse became very sick. Mouse 509631 was sacrificed at the time of high titer detection, and the lungs of this
animal showed neuroendocrine lesions in situ, but cancer was not detected. Crosses indicate dates of sacrifice. Titer values are in thousands.
(B-E) Mice carrying homozygously floxed p53 and Rb alleles, as well as a luciferase reporter under the control of a b-actin promoter, were
infected with adenovirus carrying the Cre recombinase gene via intratracheal instillation. Mice were monitored for tumor formation using
bioluminescence detection (B, C, left panels, and D), X-ray based CT-scan (B and C, right panels, open circles, heart; arrowheads, tumor mass),
and clinical symptoms like weight loss (E), altered coat, or kyphosis. B-E show the follow up of mouse 484305 which showed anti-Hu reactivity
with a titer of 80,000 at 180 days (arrows) after Adeno-Cre infection. At that time, tumor was undetectable by imaging techniques (images taken
203 and 256 days after Adeno-Cre infection) (B). Tumor became detectable 256 days after Adeno-Cre infection (C). Acute weight loss was
observed 286 days after Adeno-Cre infection (E). (Reprinted from [48], with permission from Elsevier, License Number 2460341062344).
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tle time between detection and metastasis for successful
intervention. Thus, it is unlikely that imaging alone will
be of use for early detection of SCLC. Some kind of
molecular marker will likely be required. However, if a
molecular assay depended on nucleic acids or protein
molecules derived from the tumor, the same problem of
tumor size would apply, since these molecules may be
secreted into the blood in undetectable amounts when
the tumor is small. This caveat may not pertain to an
antibody response; it is unknown what size a SCLC
tumor must be to trigger immune reactivity.
Autoantibodies against tumor-associated antigens are
more stable and specific than other serum-derived pro-
teins [158], making them good candidate biomarkers for
cancer detection. Because the natural history of SCLC is
unknown, it is possible that small tumors or precancer-
ous lesions may be present in patients for a long time
before the tumors develop metastatic abilities. Many
patients have smoked for decades before they develop
SCLC. Depending on the proteins they express, preneo-
plastic lesions might trigger an immune response. In
SCLC patients with paraneoplastic disease, the immune
response is frequently noted before the tumor is
detected [75]. It is, however, unclear if the timing of
events is similar in SCLC patients without PNS. In our
studies of the immune response in SCLC-prone mice,
we observed one mouse with high titer antibodies and
in situ neuroendocrine lesions, but no invasive cancer
[48]. This, and other observations from the SCLC
mouse model, support the notion that an immune
response can precede clinical detection (Figure 2). How-
ever, the window of detection in the mouse model is
small (several months at best). It remains to be seen
how the timing of events in this genetically engineered
mouse model system translates to the human situation
in which (epi)genetic alterations, potentially occurring
over the course of many years, result in the develop-
ment of SCLC. Despite this drawback, at this time, the
SCLC mouse model system offers the best tool to gain
insight into the temporal relationship between SCLC
development and the immune response. Studies of a lar-
ger number of mice, including analysis of their lungs as
elevated titers of antibodies develop, will hopefully shed
light on the type of lesions that are present when the
autoimmune response is triggered.
Identifying biomarkers highly specific for a malignant
condition is one great challenge in developing a serolo-
gical detection tool. In the case of autoantibodies, multi-
ple environmental factors, pathogen invasion, and
autoimmune disease can result in the production of a
high-level of IgG and IgM autoantibodies that recognize
various antigens and thus reduce the specificity of the
antibody [159-161]. The prevalence of smoking in
healthy individuals may also affect their immune
response (reviewed in [162]). In addition, the detection
of background reactivity may be influenced by technol-
ogy; the more sensitive the technique, the greater the
probability that background reactivity will be detected.
A recent study analyzed a panel of tumor-associated
autoantibodies in 205 healthy individuals and found a
subgroup of individuals that showed elevated levels of
immunoreactivity against most of the antigens tested
[163]. Unfortunately, no SCLC-associated antigens were
examined in this study. In another analysis, the presence
of anti-Hu reactivity was examined in plasma from 120
subjects, including 79 healthy controls (smokers and
non-smokers) and 41 SCLC cases [52]. The latter was a
population-based study matched on age, race, sex, and
smoking status in which anti-Hu reactivity was exam-
ined in relation to lung cancer risk. Although anti-Hu
reactivity was found to be significantly higher in cases
than controls, low level anti-Hu reactivity was detected
in healthy non-smokers (~39%) as well as smokers
(~44%). Dalmau and colleagues also observed anti-Hu
reactivity in non-cancer individuals; they considered
reactivity in normal subjects as background and used it
as cut-off to score anti-Hu reactivity in SCLC patients
with and without PEM/SN [26]. In other studies, reac-
tivity of anti-VGCC autoantibodies in normal controls
was used as a cut-off for positive reactivity [66,164]. The
presence of background reactivity in non-cancer patients
will likely limit the specificity of any anti-Hu antibody-
based SCLC test, and will require the stringent determi-
nation of cut-off values for reactivity considered positive.
Background reactivity does not appear to occur for all
antigens. In a study examining anti-recoverin response,
no healthy individuals showed positive reactivity [87].
However, SCLC is not the only cancer associated with
anti-recoverin antibodies, which can also be found in
several other cancers (Figure 1). No anti-SOX1 antibo-
dies were found in healthy individuals in another study
testing the sera of 27 healthy blood donors [165]. These
examples illustrate that careful choices must be made
when considering which SCLC antigens might be useful
for early detection tests.
The second big challenge in developing a serological
detection tool is to attain sufficient sensitivity.I ti sc l e a r
that a detection test utilizin ga n ys i n g l eS C L Ca n t i g e n
will show insufficient sensitivity because any single anti-
body is present in only a fraction of SCLC patients
(Table 1). However, examination of autoantibody reac-
tivity in SCLC patients shows that different patients can
exhibit distinct immune responses and in some occa-
sions, an immune response against multiple antigens
[29,31,166,167]. Thus, a panel of SCLC-related autoanti-
gens may provide the necessary increased sensitivity, as
was seen, for example, by Titulaer and colleagues when
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ronal Hu antigens in SCLC patients with and without
LEMS [31]. The authors from this study find 67% sensi-
tivity and 95% specificity in discriminating between
SCLC patients with LEMS and LEMS patients without
tumors when testing against a panel of the SOX family
members (Sox 1, 2, 3, and/or 21) [31]. This latter study
underlines the need to continue searching for new
SCLC-associated autoantigens.
Will a combination of antigens ever attain the required
sensitivity? To try to answer this question, we can examine
two extreme hypothetical situations. In one, all patients
show non-overlapping immune responses against different
autoantigens. In this case, a panel may greatly increase
sensitivity; the sum of the percentages of all SCLC patients
immuno-positive for currently known antigens would
allow detection of SCLC in 100% of patients (see Table 1).
In the opposite scenario, immunoreactivity is only ever
present in the same small subset of SCLC patients that
could exhibit a wide variety of antibodies. In this case, the
sensitivity one could achieve using a panel of antigens
might be as small as 25%. The latter scenario is unlikely.
For example, no correlation between the presence of anti-
Hu and anti-VGCC autoantibodies was found in 200
newly diagnosed lung cancer patients. Although four
patients were positive for both autoantibodies, individually,
up to 25.5% and 5% were immuno-reactive against Hu
proteins and VGCC, respectively [50]. Thus, the combina-
tion of carefully selected antigens may ultimately provide a
marker panel that could be of use for early SCLC detec-
tion. Indeed, recent studies show that sensitivity and speci-
ficity is greatly enhanced when a combination of
antibodies is used to detect lung cancer [31,168,169].
Aside from careful choices of markers, defining an at-risk
group that could be screened for early disease would be
crucial to increase the feasibility of any test. In the case of
SCLC, longtime heavy smokers would be prime candidates
for screening. When examining anti-Hu reactivity in
smoking and non-smoking healthy controls [52], one of
the smoking controls with detectable anti-Hu reactivity
and healthy at the time of the study died of SCLC several
years after the conclusion of the study. Based on the
expected frequency of lung cancer in this group and the
relatively minor contribution of SCLC, the SCLC case is
remarkable. However, such incidental findings are impos-
sible to interpret. In addition, three highly anti-Hu positive
cases did not develop SCLC within the time frame of the
study. Interestingly, one of the anti-Hu positive cases died
of prostate cancer, which can occasionally exhibit anti-Hu
antibodies (Figure 1A) and can show a neuroendocrine
“small cell” type [89].
It is clear that questions of sensitivity and specificity
of a combined panel of SCLC-associated autoantigens
for detection of SCLC will require further study.
A retrospective study using plasma/serum collected
from a lung cancer cohort, such as from the Carotene
and Retinol Efficacy Trial (CARET) study [170] and the
Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer
Screening Trial [171], couldp r o v i d ei n s i g h ti n t ot h e
potential of such antibodies for early cancer detection.
However, a large prospective study would ultimately be
required. Before any such study would be possible,
stronger data justifying the feasibility of autoantibody
markers for early SCLC detection would be needed. To
this end, further analysis of the SCLC-prone mouse
model system [48,131] could provide important data on
the potential sensitivity and specificity of antigen panels.
While early detection of SCLC would be the holy
grail, a much simpler application of SCLC-associated
autoantibodies is the establishment of a diagnosis. If the
timing of autoantibody generation does not precede can-
cer development, or does not precede it by sufficient
time, these antibodies would still be useful tools to
establish or confirm a SCLC diagnosis. In PNS patients,
detected autoantibodies often trigger a tumor search.
One could envision that an antigen panel to confirm
suspected SCLC could be established. Retrospective stu-
dies of archival human serum and plasma aimed at
exploring SCLC-associated antibodies for early detection
will provide data that would also be very useful to deter-
mine utility for diagnosis. Ultimately, however, a pro-
spective study in which serum and plasma from
suspected SCLC are tested and correlated with the con-
firmed clinical diagnosis, would be required.
Survival and prognostic benefits of a SCLC-associated
immune response
How could SCLC-associated autoantibodies affect survi-
val? For one, in patients exhibiting neurological symp-
toms, a diagnosis of SCLC-related autoimmunity will
prompt a tumor search, which would allow the cancer
to be detected at an earlier time point when interven-
tion might be more effective. The fact that autoantibo-
dies can precede the diagnosis of the tumor [172,173]
suggests the cancer can still be very small, and it opens
a window for improving the overall outcome in these
patients, perhaps by beginning antitumor treatment
before metastasis occurs.
Secondly, the immune response may itself be protec-
tive. A number of studies suggest that patients with
SCLC-related autoimmune disease have a better prog-
nosis than patients with histologically identical tumors
without a paraneoplastic disorder [139,174-176]. The
fact that some PEM/SN patients have small or virtually
undetectable SCLC lesions that are only identifiable at
autopsy supports this observation [42]. Furthermore, it
has been reported that in SCLC patients without para-
neoplastic disease, low titers of anti-Hu autoantibodies
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growth relative to antibody-negative patients [42,88].
The presence of other SCLC-associated autoantibodies
(VGCCs, CV2/CRMP5) in patients has been correlated
to slower tumor growth, complete response to therapy,
and longer survival in some studies [32,41,42,52,
88,137-142]. Other studies, however, have found no
survival benefit in correlation with SCLC-associated
autoantibodies [28,31,50,88,143,144]. This discrepancy
may be due to sample size, treatment protocols, second-
ary endpoints used to measure survival, the nature of
the antibodies, the presence of clinical features, and
whether or not the clinical status of the patient is
known at the close of the study.
Abnormal or ectopic expression of antigens by a non-
neuronal cell type could activate immuno-competent
cells that promote an inflammatory response. The
inflammatory response can trigger apoptosis, which
could then initiate an antitumor immune response
[22,108]. Apoptosis of tumor cells can expose intracellu-
lar antigens, mediating an immune response to self-anti-
gens that are expressed both in the tumor and the
nervous system [177-179]. Furthermore, tumor cells can
be phagocytosed by dendritic cells that further activate
antigen-specific CD4+ and CD8+ T cells and B cells
through normal immunologic processes. These anti-
body-producing B cells could act in concert along with
cytotoxic T cells specific for the tumor antigen and
induce cytotoxicity, potentially retarding tumor growth.
The antibodies could trigger complement-mediated
cytotoxicity [180] or antibody-dependent cell-mediated
cytotoxicity [181]. Furthermore, the antibodies may bind
to their target and interfere with the function of the
antigen. This might disrupt tumor progression if the
antigen is necessary for tumor growth. The latter
may provide an explanation for how tumors in some
antibody-positive SCLC patients are smaller or slower
growing. Definitive evidence of this theory is lacking,
however. The nature of the immuno-response in SCLC
requires further characterization to determine the pro-
tective nature of antibodies and T cells. Again, the
SCLC-prone mouse model discussed in Section 5 would
be a useful resource to study this phenomenon.
SCLC autoantigens as targets for anti-cancer therapy and
imaging
The development of SCLC vaccines presents a formid-
able challenge because an immune response against
antigens expressed both in the tumor and nervous sys-
tem may cause neurotoxicity. The main objective in
treating a patient with SCLC-related PNS is to cure the
underlying cancer and to improve or stabilize the neuro-
logical dysfunction [140]. Interestingly, in mice that
were implanted with neuroblastoma, immunization with
DNA encoding HuD has been shown to retard tumor
growth [110,111], and the mice did not develop neurolo-
gic abnormalities in this study nor in a study where
mice were immunized with recombinant purified HuD
antigen [111]. The SCLC-prone mouse model [131] can
be utilized in a similar manner to determine if immuni-
zation with various SCLC-associated autoantigens would
protect against the development of the SCLC tumor;
however, neurotoxicity is a potential side effect and
would need to be closely monitored.
A very different situation arises if the antigens triggering
the immune responses are mutated or post-translationally
modified in the tumor compared to the native nervous
system. In that case, a strategy to specifically target the
modification would be an option. However, when using
immunizations aimed at inducing a cancer-specific
response to a modified protein, a unique tumor-specific
epitope may not preclude a destructive autoimmune
response; reactivity might expand through epitope spread-
ing. For any immunotherapy strategy, finding the right
balance between attacking the tumor and avoiding neuro-
toxicity is imperative. A more promising avenue may be to
develop molecules tailored to recognize the antigen using
in vitro evolution in small scaffolds, like knottin peptides
[182]. Such “magic bullets” could be targeted toward any
cancer-specific modification to deliver molecules for ima-
ging or treatment. Visualization of small tumors is critical
to establish the precise location to perform successful
resection. Most current imaging modalities are not specific
for cancer, although metabolism-based markers show
higher signals in cancer cells based on their increased
metabolic activity. Imaging agents specifically targeted to
cancer cells can be powerful aids in cancer detection and
could increase our ability to detect small SCLC lesions.
The potential to use the immune system or targeted
molecules to attack the tumor underlines the impor-
tance of obtaining a detailed mechanistic understanding
of SCLC-associated autoimmunity. Until the nature
of the antigen and the immune response are clarified,
it will be very difficult to devise fruitful applications.
The biggest challenge may be that different SCLC-
associated immune responses may occur through dis-
tinct mechanisms.
Conclusions
Identifying SCLC-associated autoantigens that may elicit
an antibody-based immune response may yield new
methods for SCLC detection, screening, treatment, and
imaging. Antibody responses against a wide variety of
antigens are seen in SCLC patients. How common these
antibodies are in patients and what the background
response is in healthy individuals varies by antigen. The
exact mechanism whereby these antibodies develop
remains to be elucidated. While the examination of
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Page 13 of 19antibodies for a single autoantigen as a diagnostic or
screening tool for SCLC would not be sufficiently sensi-
tive given the fact that only a fraction of SCLC patients
shows a response to any given antigen, in theory, a
panel of antigens might be used to detect antibodies in
the blood of those at most risk for SCLC. It is unclear
whether such a panel could provide high enough sensi-
tivity and specificity and whether the antibodies arise
with enough lead time to allow intervention with an
appreciable impact on survival. Effective intervention
would only be possible if the tumor could be resected
before it metastasizes or if improved treatments become
available. Establishing the timing of an autoimmune
response relative to cancer development is therefore of
great importance. The identification of the autoimmune
trigger (if it is distinct from the wildtype neuron-specific
protein) in the different SCLC-associated PNS is crucial.
Any identified epitopes might be of use as therapeutic
targets, for example using tailored antibodies or syn-
thetic molecules. A recently developed SCLC mouse
model that has been shown to develop an anti-Hu
response provides powerful new tool for investigation in
this important field, and could provide insight into
many of the questions raised above.
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